Assessing genomic instability (GI) by shallow whole-genome sequencing (sWGS) to predict PARP inhibitor (PARPi) response in metastatic castration-resistant prostate cancer (mCRPC). Homologous ...
Prevalence of EGFR Mutations in Patients With Resected Stage I to III Nonsquamous Non–Small Cell Lung Cancer: Results of India Cohort In total, 232 fellowship programs exist in the surveyed nations, ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
A phase 2/3 multicenter trial evaluating safety and efficacy of a new mucoadhesive gemcitabine suspension for ablation of upper tract urothelial carcinoma. ABLE-22: Safety and efficacy evaluation of ...
CFO: Calibration-Free Odds Bayesian Designs for Dose Finding in Clinical Trials ...
Extracellular DNA in patients with urothelial carcinoma of the bladder. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does not include a full text ...
Avelumab first-line maintenance (1LM) in patients (pts) with advanced urothelial carcinoma (aUC) with or without diabetes mellitus (DM): Long-term outcomes from JAVELIN Bladder 100. Sarcopenia as a ...
Association between proto-oncogene N-RAS transcript level and overall survival in node-negative muscle-invasive urothelial bladder carcinoma.
COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts Data were from a retrospective chart review of patients with ...
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma A total of 121 patients (previous ICI-treated cohort, n = 31, and each of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback